Home Cellular health Scientists Tackle Sussex Attack On Pharmaceuticals Not Sharing Vaccine Revenues

Scientists Tackle Sussex Attack On Pharmaceuticals Not Sharing Vaccine Revenues



“Relinquishing intellectual property rights to Covid-19 vaccines will not increase production and provide the practical solutions needed to tackle this global health crisis. As we have always said, a waiver is the simple, but mistaken, answer to what is a complex problem.

“As we now have billions of vaccines that have been produced and many more in the works, calls for waiver of intellectual property are a distraction. “

Mr Cueni added that the real challenges are trade barriers, supply chain bottlenecks, lack of raw materials and the reluctance of rich countries to share the doses.

The solution to vaccine apartheid is political leadership, he says, as there are 1.2 billion doses available between the UK, US, EU and Canada.

“These figures are proof that the intensification of vaccine manufacturing is such that the problem is not the shortage of supply, the problem is redistribution,” Cueni said.

Giving up intellectual property “won’t solve vaccine inequity”

Dr Michael Head, Senior Global Health Researcher at the University of Southampton, added: “The level of inequity in vaccine deployment is unacceptable. A publication of vaccine intellectual property would be useful, but it would not in itself resolve the inequity. Many variables have contributed to this unsatisfactory situation.

Dr Simon Clarke, Associate Professor of Cellular Microbiology at the University of Reading, said: “People often assume that there is only one patent behind every vaccine, there is not, there are multiple patents. and they should all be open.

“With RNA vaccines in particular, I don’t think there are a lot of places in the developing world that could make them on a large scale.”